The Immune cell engineering market consists of engineered immune cells that are manipulated genetically to recognize specific disease cells and eradicate them from the body. Immune cells such as T cells, NK cells, and dendritic cells are engineered ex vivo by introducing new therapeutic genes or CAR receptors to redirect them against diseased cells. The engineered cells are then expanded and infused back into patients to induce disease regression. These therapies are advantageous in combating various cancers and autoimmune diseases by specifically targeting disease cells while leaving healthy cells unharmed.
The global immune cell engineering market size is expected to reach US$ 14.30 Bn by 2031, from US$ 3.45 Bn in 2024, at a CAGR of 22.5% during the forecast period. Key Takeaways
Key players operating in the Immune cell engineering are Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd.
The growing prevalence of various cancers and infectious diseases is expected to drive the demand for immune cell engineering therapies. Furthermore, the successful development and commercialization of CAR T-cell therapies has accelerated research and development activities in immune cell engineering. Various companies are also expanding their immune cell engineering facilities globally to cater to the increasing demand. Market Key Trends
One of the key Immune Cell Engineering Market Trends is the development of therapies using multiple cell types. Several clinical trials are exploring the use of combining T cells with other immune cells like NK cells or dendritic cells to enhance therapeutic efficacy. For instance, clinical trials are evaluating the use of NK cells together with CAR T cells or TILs to leverage the complementary anti-tumor activities of different cell types. Combination therapies have the potential to induce better and more durable clinical responses compared to single cell therapies. This emerging trend of multi-cell therapies is expected to be a major driver of future growth in the immune cell engineering market.
Porter's Analysis
Threat of new entrants: New entrants face high initial costs for developing immune cells and therapies.
Bargaining power of buyers: Individual patients have little bargaining power whereas large healthcare providers and private insurers have significant bargaining power.
Bargaining power of suppliers: Suppliers of raw materials and reagents have moderate bargaining power due to availability of substitutes.
Threat of new substitutes: Development of new drug delivery methods and gene and cell therapy techniques pose a threat of substitution.
Competitive rivalry: Companies compete based on technological advances, clinical trial results, and intellectual property protection. Accroding to Immune Cell Engineering Market Regional Analysis,The geographical region is currently concentrated in terms of value is North America. The region accounts for the largest share, followed by Europe and Asia Pacific. This can be attributed to the presence of well-established healthcare systems, high healthcare spending, growing biotechnology industry, and availability of sophisticated research infrastructure in these regions. The fastest growing region for the immune cell engineering market is expected to be Asia Pacific owing to increasing healthcare expenditure, large patient population, expansions by key market players, rising awareness about advanced cell therapies, and improvements in research capabilities in emerging countries such as China and India.
Discover the Report for More Insights, Tailored to Your Language.
French German Italian Russian Japanese Chinese Korean Portuguese
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
